Nature's Sunshine Products, Inc. (NATR) Cash Flow Statement

The prior three quarters (2025Q3 through 2025Q4) posted OCF/NI ratios of 3.46, 2.41 and 0.81, so the swing to negative conversion is abrupt rather than gradual and appears disconnected from the reported profitability improvement flagged in the income statement work. Because D&A and SBC remained positive and roughly stable in 2026Q1–Q2, the conversion gap is not a non-cash addback story — it sits almost entirely in working capital, which means reported operating margin gains are, on current evidence, not translating into spendable cash. Investors should treat the 2025Q3's 13.1% FCF margin as a high-water mark that may have reflected temporary working capital release rather than a new run-rate.

Two consecutive quarters of large draws (-$14.8M and -$24.1M) offset the cumulative working capital releases of 2024Q3 through 2025Q3, suggesting the earlier cash tailwind has reversed rather than simply paused. In a direct-selling model this pattern is consistent with distributor receivable or inventory dynamics, though the magnitude and speed of the reversal cannot be reconciled to the modest revenue deceleration (1.9% growth in 2026Q2) on the disclosed data and warrants investigation into receivable aging and distributor prepayment trends. If the draw persists at even half the 2026Q2 pace, operating cash flow would remain structurally negative despite positive net income.

The 2025Q2–2025Q3 sequence (FCF of $3.0M then $16.8M) created the appearance of an upward FCF trajectory that the last two quarters have fully unwound, leaving the trend line essentially flat around a low-single-digit margin. Given that net income has stayed in a tight $3.5M–$5.3M band for six consecutive quarters, the FCF volatility is being driven by cash timing rather than earnings, which materially reduces the predictive value of any single quarter's FCF print. On a two-year view, cumulative FCF of ~$32.7M against cumulative net income of ~$35.7M indicates the business converts over a cycle, but with timing risk that makes quarterly cash generation an unreliable signal.

The 2026Q2 step-up to 4.5% of revenue (from 2.0% in 2026Q1) is the highest reading in the series and arrives in the same quarter as the largest working capital draw, so the modest capital escalation is compounding rather than cushioning the cash shortfall. Because capex has historically sat close to D&A, there appears to be limited discretionary room to cut investment as a cash lever — maintenance needs appear to absorb most of what is spent. The implication is that any operating cash shortfall must be resolved through working capital or balance sheet actions rather than capital deferral.

Concentrating all shareholder returns in opportunistic repurchase means deployment is discretionary and can be paused, which is a defensive feature given the current operating cash draw — and the pattern suggests management has already slowed activity ($0.5M in 2026Q1 versus $11.9M in 2025Q2). The single $6.2M net acquisition outflow in 2025Q4 is modest relative to the ~$32.7M of cumulative two-year FCF, indicating inorganic activity has not been a meaningful cash sink and limiting dilution risk to the equity base. Investors should monitor whether the absence of a dividend, unusual for a consumer defensive name with this cash history, signals an intentional reserve build ahead of anticipated working capital needs.